Sagimet Biosciences (STU:0O2) Net Income Including Noncontrolling Interests: €-37.39 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:0O2 Sagimet Biosciences Inc STU:0O2
38 GF Score
Price €6.88
! 3 Warning Signs
View Full Analysis

What is Sagimet Biosciences Net Income Including Noncontrolling Interests?

Sagimet Biosciences STU:0O2 +10.97% 38 Net Income Including Noncontrolling Interests is €-37.39 Mil as of Mar. 2026. GuruFocus rates STU:0O2 with a GF Score™ of 38/100. The stock has 3 warning signs investors should review.

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Sagimet Biosciences's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2026 was €-9.21 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2026 was €-37.39 Mil.

Sagimet Biosciences Net Income Including Noncontrolling Interests Related Terms

Sagimet Biosciences Net Income Including Noncontrolling Interests Historical Data

* Premium members only.

The historical data trend for Sagimet Biosciences's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sagimet Biosciences Net Income Including Noncontrolling Interests Chart

Sagimet Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial -21.63 -28.79 -25.56 -43.52 -43.59

Sagimet Biosciences Quarterly Data
Dec20 Mar21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16.81 -9.01 -11.00 -8.17 -9.21
STU:0O2
38GF Score
Sagimet Biosciences Inc STU:0O2
Net Income Including Noncontrolling Interests is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sagimet Biosciences Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-37.39 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income Including Noncontrolling Interests of €-37.39 Mil mean?
Sagimet Biosciences (STU:0O2) has a Net Income Including Noncontrolling Interests of €-37.39 Mil as of Mar. 2026.
Is Sagimet Biosciences' Net Income Including Noncontrolling Interests too high?
Sagimet Biosciences' current Net Income Including Noncontrolling Interests is €-37.39 Mil. Overall, Sagimet Biosciences has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Sagimet Biosciences' Net Income Including Noncontrolling Interests compare to CABA and OVID?
Sagimet Biosciences' Net Income Including Noncontrolling Interests of €-37.39 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income Including Noncontrolling Interests for a Biotechnology company?
A good Net Income Including Noncontrolling Interests depends on the Biotechnology industry context. However, Net Income Including Noncontrolling Interests should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income Including Noncontrolling Interests mean?
A high Net Income Including Noncontrolling Interests can signal that a stock is expensive relative to its fundamentals. Sagimet Biosciences's current Net Income Including Noncontrolling Interests is €-37.39 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sagimet Biosciences stock overvalued right now?
Sagimet Biosciences (STU:0O2) has a current Net Income Including Noncontrolling Interests of €-37.39 Mil. The current Net Income Including Noncontrolling Interests is €-37.39 Mil. Sagimet Biosciences' overall GF Score™ is 38/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income Including Noncontrolling Interests calculated?
Net Income Including Noncontrolling Interests is calculated from a company's financial statements. For Sagimet Biosciences (STU:0O2), the current Net Income Including Noncontrolling Interests is €-37.39 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sagimet Biosciences Business Description

Other Exchanges SGMT:USA
Address 155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
38GF Score

Get the complete analysis for STU:0O2

Net Income Including Noncontrolling Interests is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.88
Price